Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipram

British Journal of Pharmacology

Volumn 140, Issue 5, 2003, Pages 855-862

  Soares, A C ^a   Souza, D G ^a   Pinho, V ^a   Vieira, A T ^a   Barsante, M M ^a   Nicoli, J R ^a   Teixeira, M ^a,b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Bacterial infection; Chemokines; Lung inflammation; Neutrophils; Phophodiesterase 4 inhibitors; TNF

Indexed keywords

BIOMOL; CHEMOKINE; CYTOKINE; INTERLEUKIN 10; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOKINESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; ENTEROBACTER INFECTION; FEMALE; HOST RESISTANCE; IC 50; KERATINOCYTE; KLEBSIELLA PNEUMONIAE; LETHALITY; LEUKOCYTE MIGRATION; LUNG INFECTION; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; ROLIPRAM;

EID: 0344441301     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705517     Document Type: Article

References (39)

1. AU, B.T., TEIXEIRA, M.M., COLLINS, P.D. & WILLIAMS, T.J. (1998). Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br. J. Pharmacol., 123, 1260-1266.
2. BARNETTE, M.S. (1999). Phosphodiesterase 4 (PDE)4 inhibitors asthma and chronic obstructive pulmonary disease (COPD). Prog. Drug Res., 63, 193-229.
3. BLEASE, K., MEHRAD, B., LUKACS, N.W., KUNKEL, S.L., STANDIFORD, T.J. & HOGABOAM, C.M. (2001). Antifungal and airway remodeling roles for murine monocyte chemoattractant protein-1/CCL2 during pulmonary exposure to Aspergillus fumigatus conidia. J. Immunol., 166, 1832-1842.
4. BROUG-HOLUB, E., TOEWS, G.B., VAN IWAARDEN, J.F., STRIETER, R.M., KUNKEL, S.L., PAINE III, R. & STANDIFORD, T.J. (1997). Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect. Immun., 65, 1139-1146.
5. COMPTON, C.H., GUBB, J., NIEMAN, R., EDELSON, J., AMIT, O., BAKST, A., AYRES, J.G., CREEMERS, J.P.H.M., SCHULTZE-WERNINGHAUS, G., BRAMBILLA, C. & BARNES, N.C. (2001). Cilomilast, a selective phosphodiesterase-4 inhibitor for the treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet, 358, 265-270.
6. DEMARSH, P.L., SUCOLOSKI, S.K., TAL-SINGER, R., WELLS, G., DILLON, S.B. & WOODNUTT, G. (2001). Effect of Cilomilast, an orally active, selective PDE4 inhibitor in a murine viral/bacterial coinfection model. Am. J. Respir. Crit. Care Med., 163, A381.
7. DE MATOS, I.M., SOUZA, D.G., SEABRA, D.G., FREIRE-MAIA, L. & TEIXEIRA, M.M. (1999). Effects of tachykinin NK1-or PAF-receptor blockade on the lung injury induced by scorpion venom. Eur. J. Pharmacol., 376, 293-300.
8. DE MORAES, V.L.G., SINGER, M., VARGAFTIG, B.B. & CHIGNARD, M. (1998). Effects of rolipram on cAMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br. J. Pharmacol., 123, 631-636.
9. GIEMBYCZ, M.A. (2002). Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch. Chest Dis., 57, 48-64.
10. GRANTON, J.T. & GROSSMAN, R.F. (1993). Community-acquired pneumonia in the elderly patient. Clinical features, epidemiology, and treatment. Clin. Chest Med., 14, 537-539.
11. GREENBERGER, M.J., STRIETER, R.M., KUNKEL, S.L., DANFORTH, J.M., GOODMAN, R.E. & STANDIFORD, T.J. (1995). Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J. Immunol., 155, 722-729.
12. + T cells during a pulmonary Cryptococcus neoformans infection. J. Immunol., 155, 4790-4797.
13. KAMBAYASHI, T., JACOB, C.O., ZHOU, D., MAZUREK, N., FONG, M. & STRASSMANN, G. (1995). Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J. Immunol., 155, 4909-4916.
14. KLEMM, P., HARRIS, H.J. & PERRETTI, M. (1995). Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. Eur. J. Pharmacol., 281, 69-74.
15. KUNG, T.T., CRAWLEY, Y., LUO, B., YOUNG, S., KREUTNER, W. & CHAPMAN, R.W. (2000). Inhibition of pulmonary eosinophilia and airway hyperrresponsiviness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines. Br. J. Pharmacol., 130, 457-463.
16. LAICHALK, L.L., KUNKEL, S.L., STRIETER, R.M., DANFORTH, J.M., BAILIE, M.B. & STANDIFORD, T.J. (1996). Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect. Immun., 64, 5211-5218.
17. MALONEY, S.A. & JARVI, W.R. (1995). Epidemic nosocomial pneumonia in the intensive care unit. Clin. Chest Med., 16, 209-223.
18. MALUS, E., CHERAPANOV, V., ARORA, A., SJOLIN, C. & DOWNEY, G.P. (2001). Selective inhibition of neutrophil function by the phosphodiesterase 4 inhibitor SB 207499. Am. J. Respir. Crit. Care Med., 163, A993.
19. MEHRAD, B. & STANDIFORD, T.J. (1999). Role of cytokines in pulmonary antimicrobial host defense. Immunol. Res., 20, 15-27.
20. MIOTLA, J.M., TEIXEIRA, M.M. & HELLEWELL, P.G. (1998). Supression of acute lung injury in mice by an inhibition of phosphodiesterase type 4. Am. J. Respir. Cell Mol. Biol., 18, 411-420.
21. MOORE, T.A., NEWSTEAD, M.W., STRIETER, R.M., MEHRAD, B., BEAMAN, B.L. & STANDIFORD, T.J. (2000). Bacterial clearance and survival are dependent on CXC chemokine receptor-2 ligands in a murine model of pulmonary Nocardia asteroides infection. J. Immunol., 164, 908-915.
22. NAKANO, Y., KASAHARA, T., MUKAIDA, N., KO, Y.C., NAKANO, M. & MATSUSHIMA, K. (1994). Protection against lethal bacterial infection in mice by monocyte-chemotactic and -activating factor. Infect. Immunol., 62, 377-383.
23. NELSON, S., SUMMER, W.R. & KAKAB, G.J. (1985). Aminophyline-induced suppression of pulmonary antibacterial defenses. Am. Rev. Resp. Dis., 131, 923-927.
24. PROCOPIO, D.O., TEIXEIRA, M.M., CAMARGO, M.M., TRAVASSOS, L.R., FEGURSON, M.A.J., ALMEIDA, I.C. & GAZZINELLI, R.T. (1999). Differential inhibitory mechanism of cAMP on TNF-α and IL-12 synthesis by macrophages exposed to microbial stimuli. Br. J. Pharmacol., 127, 1195-1205.
25. SANZ, M.J., ALVAREZ, A., PIQUERAS, L., CERDÁ, M., ISSEKUTZ, A.C., LOBB, R.R., CORTIJO, J. & MORCILLO, E.J. (2002). Rolipram inhibits leukocyte-endothelial cell interaction in vivo through P- and E-selectin down-regulation. Br. J. Pharmacol., 135, 1872-1881.
26. SCHIMIDT, D., DENT, G. & SARGENT, C. (1999). Selective phosphodiesterase inhibitors in the treatment of bronchial asthma and obstructive pulmonary disease. Clin. Exp. Allergy, 29, 99-109.
27. SEKUT, L., MENIUS, J.A., BRACKEEN, M.F. & CONNOLLY, K.M. (1994). Evaluation of the significance of elevated levels of systemic and localized tumor necrosis factor in different animal models of inflammation. J. Lab. Clin. Med., 124, 813-819.
28. SEKUT, L., YARNALL, D., STIMPSON, S.A., NOEL, L.S., BATEMAN-FITE, R., CLARK, R.L., BRACKEEN, M.F., MENIUS, J.A. & CONNOLY, K.M. (1995). Anti-inflammatory activity of phosphodiesterases (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol., 100, 126-132.
29. SELDON, P.M., BARNES, P.J. & GIEMBYCZ, M.A. (1998). Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes. Cell Biochem. Biophys., 29, 179-201.
30. SOARES, A.C., PINHO, V., SOUZA, D.G., NICOLI, J.R. & TEIXEIRA, M.M. (2002). Role of the platelet-activating factor (PAF) receptor during pulmonary infection with gram negative bacteria. Br. J. Pharmacol., 137, 621-628.
31. SOUNESS, J.E., ALDOUS, D. & SARGENT, C. (2000). Immunosupressive and anti-inflammatory effects of cAMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacol., 47, 127-162.
32. SOUZA, D.G., CASSALI, G.D., POOLE, S. & TEIXEIRA, M.M. (2001). Effects of inhibition of PDE4 and TNF-α on local and remote injuries following ischemia and reperfusion injury. Br. J. Pharmacol., 134, 985-994.
33. SOUZA, D.O., SOARES, A.C., PINHO, V., TORLONI, H., REIS, L.F.L., TEIXEIRA, M.M. & DIAS, A.A. (2002). Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am. J. Pathol., 160, 1755-1765.
34. TEIXEIRA, M.M., CUNHA, F.Q. & FERREIRA, S.H. (2001). Editorial. Response to an infectious insult. Braz. J. Med. Biol. Res., 34, 1p (preceding 555).
35. TEIXEIRA, M.M., GRISTWOOD, R.W., COOPER, N. & HELLEWELL, P.G. (1997). Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trend Pharmacol. Sci., 18, 164-170.
36. TEIXEIRA, M.M., WILLIAMS, T.J. & HELLEWELL, P.G. (1994). Effect of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea pig. Br. J. Pharmacol., 112, 332-340.
37. TORPHY, T.J. (1998). Phosphodiesterase isozymes molecular targets for novel antiasthma agents. Am. J. Resp. Care Med., 157, 351-370.
38. TSAI, W.C., STRIETER, R.M., MEHRAD, B., NEWSTEAD, M.W., ZENG, X. & STANDIFORD. T.J. (2000). CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect. Immun., 68, 4289-4296.
39. WANG, P., WU, P., SIEGEL, M.I., EGAN, R.W. & BILLAH, M.M. (1995). Interleukin (IL)-10 inhibits nuclear factor κB (NFκB) activation in human monocytes. IL-10 and IL-4 supress cytokine synthesis by different mechanisms. J. Biol. Chem., 270, 9558-9563.